Finances improving

Scarcity necessitates choice how can resources be used to best effect What criteria might we use in making those decisions One of the most important will be effectiveness— the abilities of treatment and support resources to improve the health and quality of life of people with mental health problems but, as we have seen, increasingly attention is also being paid to the costs of achieving those effects. The generic term for the criterion that combines effectiveness with resource considerations is efficiency. A third criterion of importance is equity or fairness in the distribution of access to treatment resources, the burden of financing them, or of their effects on health and quality of life. 

For energy suppliers, TES lowers generating equipment costs (by 30-50% for air-conditioning loads), reduces financing requirements (by USS1-2 billion), and improves customer retention. 

In recent years in some developed countries, the requisite of presenting economic evaluation (that is, pharmacoeconomic) studies of new dmgs has been introduced alongside the existing one of clinical trials. These studies have to provide proof of their efficiency (or cost-effectiveness) as a condition for the public financing of the new product. These studies improve information and market transparency and may help to make competition keener, but like the earlier requirements regarding effectiveness and safety, they constitute an additional cost factor and as such raise further barriers to entry. 

However, the extensive and varied experience undergone in Europe and its trend towards greater participation by the user in the financing of pharmaceuticals does not seem to have made any substantial contribution to cost containment. Practically all European countries use drag co-payment with the imphcit objective of making the user jointly responsible for the cost, but not as an essential source of revenue for the public health care system, nor has it proved to be a political instrument with the ability to contain costs or substantially improve efficiency. 

It is tempting for environmentalists to ignore economics and finance. After all, they say, the environment is more important than mere money. However, in the real world - where the rest of us live - we too want to improve and protect the environment, but this costs money and we recognise that without infinite resources we have to prioritise where we spend our money. We also recognise that if business does not make profits there will not be any money to spend So I make no apology for addressing the economics of cellroom conversion. 

Seek financing for more expensive and comprehensive system improvements. 

Department of Health and Hnman Services, Health Care Financing Administration (1992) Clinical Laboratory Improvement Amendments of 1988 Final Rule. Federal Register 57,7001-7288. 

Improving access to essential medicines is perhaps the most complex challenges to all actors in the public, private and NGO (non-government organization) sectors involved in the field of medicines supply. They must all combine their efforts and expertise, and work jointly towards the solutions. Many factors define the level of access, such as financing, prices, distribution systems, appropriate dispensing and use of essential medicines. 

One lover of snuffboxes was Napoleon, who it is reputed consumed 1 kg of snuff a week Napoleon also Improved France s finances by enforcing tobacco taxation and his armies found tobacco a useful appetite suppressant when food supplies were limited. 

---